Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

475
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
475
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology01:29

Gastroesophageal Reflux Disease I: Meaning and Pathophysiology

417
Gastroesophageal Reflux Disease (GERD) involves the recurrent backflow of the stomach or duodenal contents into the esophagus, leading to troublesome symptoms and potential esophageal mucosal damage. Although GERD is often referred to as a disease, it is more accurately described as a syndrome, as it encompasses a range of symptoms and complications rather than a singular pathological entity, impacting a large number of individuals as the most prevalent upper gastrointestinal problem. Roughly...
417
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

167
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
167
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

415
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
415
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

526
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
526
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

890
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
890

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Klebsiella genus as driver of human disease: from infections to non-communicable disorders.

Nature reviews. Microbiology·2026
Same author

IBDome: An Integrated Molecular, Histopathological, and Clinical Atlas of Inflammatory Bowel Diseases.

Gastroenterology·2026
Same author

Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease.

Life (Basel, Switzerland)·2026
Same author

Anti-TNF therapies in autoimmune hepatitis: Promises and challenges.

Journal of hepatology·2026
Same author

<i>Escherichia-Shigella</i> expansion and metabolite dysregulation in type 3c diabetes: linking microbiome alterations to exocrine pancreatic insufficiency.

Frontiers in endocrinology·2026
Same author

Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023.

eGastroenterology·2026

Related Experiment Video

Updated: Aug 26, 2025

A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis
09:18

A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis

Published on: July 28, 2023

2.8K

Gut-liver axis: Pathophysiological concepts and clinical implications.

Herbert Tilg1, Timon E Adolph1, Michael Trauner2

  • 1Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University, Innsbruck, Austria.

Cell Metabolism
|October 8, 2022
PubMed
Summary
This summary is machine-generated.

The gut-liver axis is a crucial communication pathway influencing gastrointestinal and liver health. Disruptions in this axis, particularly in liver cirrhosis, drive inflammation and disease complications.

Keywords:
gut microbiomegut-liver axisleaky gutliver disease

More Related Videos

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

9.6K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.3K

Related Experiment Videos

Last Updated: Aug 26, 2025

A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis
09:18

A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis

Published on: July 28, 2023

2.8K
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

9.6K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.3K

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiology
  • Immunology

Background:

  • The gut-liver axis involves bidirectional communication influencing gastrointestinal and liver health.
  • Host-microbe interactions are modulated by nutrients, microbial metabolites, and bile acids.
  • Impaired intestinal barrier function exacerbates hepatic inflammation and disease progression.

Purpose of the Study:

  • To elucidate the mechanisms of gut-liver crosstalk in health and disease.
  • To investigate the role of host-microbe interactions in liver diseases.
  • To identify potential therapeutic targets for liver conditions.

Main Methods:

  • Review of clinical evidence and experimental models of liver disease.
  • Analysis of host-microbe interactions, including microbial community structure and function.
  • Examination of metabolic interplay and immune responses along the gut-liver axis.

Main Results:

  • Perturbations in gut-liver crosstalk are evident in non-alcoholic fatty liver disease, alcoholic liver disease, and primary sclerosing cholangitis.
  • In liver cirrhosis, gut microbiota and microbial products promote liver inflammation and complications like hepatic encephalopathy.
  • Impaired intestinal barrier function is a key factor in disease progression.

Conclusions:

  • Understanding the gut-liver metabolic interplay is vital for developing targeted therapies.
  • Modulating host-microbe interactions presents a promising therapeutic strategy for liver diseases.
  • Further research and clinical trials are needed to explore these therapeutic avenues.